The adenosine A2A receptor is specifically enriched in the medium spiny neurons that make up the ‘indirect’ output pathway from the ventral striatum, a structure known to have a crucial, integrative role in processes such as reward, motivation, and drug-seeking behavior. In the present study we investigated the impact of adenosine A2A receptor deletion on behavioral responses to morphine in a number of reward-related paradigms. The acute, rewarding effects of morphine were evaluated using the conditioned place preference paradigm. Operant self-administration of morphine on both fixed and progressive ratio schedules as well as cue-induced drug-seeking was assessed. In addition, the acute locomotor response to morphine as well as sensitization to morphine was evaluated. Decreased morphine self-administration and breakpoint in A2A knockout mice was observed. These data support a decrease in motivation to consume the drug, perhaps reflecting diminished rewarding effects of morphine in A2A knockout mice. In support of this finding, a place preference to morphine was not observed in A2A knockout mice but was present in wild-type mice. In contrast, robust cue-induced morphine-seeking behavior was exhibited by both A2A knockout and wild-type mice after a period of withdrawal. The acute locomotor response to morphine in the A2A knockout was similar to wild-type mice, yet A2A knockout mice did not display tolerance to chronic morphine under the present paradigm. Both genotypes display locomotor sensitization to morphine, implying a lack of a role for the A2A receptor in the drug-induced plasticity necessary for the development or expression of sensitization. Collectively, these data suggest a differential role for adenosine A2A receptors in opiate reinforcement compared to opiate-seeking.
Adenosine is a ubiquitous purine nucleoside that has a fundamental role in governing the physiological function of cells, including the processes underlying neurotransmission (for review, see Dunwiddie, 1985; Snyder, 1985; Brundege and Dunwiddie, 1997). Four adenosine receptors belonging to the family of G-protein-coupled receptors have been identified thus far: the A1, A2A, A2B, and A3 receptors (Fredholm et al, 2001b, 1994). Of the known adenosine receptor subtypes, A1 and A2A receptors are primarily responsible for the central effects of adenosine (Fredholm et al, 2001a).
In contrast to the widespread distribution of A1, A2B, and A3 receptors within the central nervous system, A2A receptors are specifically enriched in the dendritic spines of striatopallidal neurons (Fink et al, 1992; Svenningsson et al, 1997; Hettinger et al, 2001; Rosin et al, 2003) where they are colocalized with dopamine D2 receptors (Fink et al, 1992; Schiffmann et al, 1991). Indeed, the formation of heterodimers between these two receptors has been demonstrated (Canals et al, 2003). Adenosine A2A receptor activation has been shown to modulate negatively the postsynaptic effects of dopamine at the biochemical, cellular, functional, and behavioral levels (Ferre et al, 1993, 1991a). Behaviorally, adenosine A2A agonists produce dopamine D2-like antagonist effects and vice versa (Ferre et al, 1997). For example, the adenosine A2A receptor agonist CGS 21680 induces catalepsy and this is counteracted by administration of the D2 antagonist BHT-920 (Ferre et al, 1991b). In addition to direct interactions with the dopamine D2 receptor, A2A receptors have been shown to interact indirectly with dopamine D1 receptors to regulate D1-mediated behavioral and cellular effects (Pollack and Fink, 1996; Pinna et al, 1996; Svenningsson et al, 1998; Short et al, 2006b).
A critical role for the mesocorticolimbic dopamine system has long been established in the rewarding properties of drugs of abuse (Di Chiara and Imperato, 1988), and a growing body of evidence exists implicating the A2A receptor in reward-related behavior. Adenosine, via A2A receptors, modulates behaviors associated with acute and chronic exposure to cannabinoids (Soria et al, 2004), psychostimulants (Chen et al, 2000; Soria et al, 2006), nicotine (Castane et al, 2006), and alcohol (Arolfo et al, 2004; Short et al, 2006b). The bulk of evidence to date concerning adenosine involvement in opiate reward centers on opiate withdrawal. Thus, adenosine agonists reduce and antagonists increase symptoms associated with precipitated opiate withdrawal (Salem and Hope, 1997; Kaplan and Sears, 1996). Increased levels of adenosine metabolites in the nucleus accumbens (NAc) have been reported to occur during opiate withdrawal in rats (Salem and Hope, 1997) and adenosine kinase inhibitors significantly reduce morphine withdrawal symptoms in mice, an effect that can be blocked by the nonselective adenosine receptor antagonist caffeine (Kaplan and Coyle, 1998). In agreement with these findings, two studies (Bailey et al, 2004; Berrendero et al, 2003) have found an enhancement in the expression of some morphine withdrawal signs in opiate-dependent A2A receptor knockout mice. These data are in apparent discord with the well-documented antagonistic relationship between adenosine A2A receptors and dopamine D2 receptors described previously and indicate a more complex role for adenosine A2A receptors in the action of opiates, potentially including nondopaminergic mechanisms.
Aside from studies relating to opiate withdrawal, a small number of pharmacological studies have provided insight into the potential involvement of the A2A receptor in other aspects of morphine reward and dependence. It has been suggested that adenosine receptor antagonists attenuate the development of morphine sensitization in mice (Weisberg and Kaplan, 1999), and nonselective adenosine antagonists inhibit morphine self-administration in rats (Sahraei et al, 1999). More recently, it was reported that administration of a selective A2A receptor antagonist eliminated reinstatement of heroin-seeking in rats (Yao et al, 2006). The comparatively low selectivity profiles of some adenosine antagonists (Yang et al, 2007) make it difficult in vivo to clarify the participation of the different adenosine receptor subtypes in opioid dependence. As yet, there has been no study examining the impact of A2A receptor deletion on aspects of morphine reward other than withdrawal. The generation of A2A receptor knockout mice with complete and specific inactivation of the A2A receptor (Ledent et al, 1997) provides a useful tool to extend these pharmacological data. The aim of the present study was to examine the effect of A2A receptor deletion on morphine reward as well as morphine-seeking behavior. The extent to which A2A receptor knockout and wild-type mice would self-administer morphine was assessed, as well as their motivation to obtain a morphine reward on a progressive ratio (PR) schedule. Cue-conditioned morphine-seeking behavior following a period of withdrawal was also measured. Differences in the ‘hedonic’ value attributed to morphine between genotypes were assessed using the conditioned place preference paradigm, and the impact of A2A receptor deletion on drug-induced plasticity was assessed using the locomotor sensitization paradigm.
MATERIALS AND METHODS
All experiments were performed in adherence to the Prevention of Cruelty to Animals Act, 1986, under the guidelines of the Australian National Health and Medical Research Council Code of Practice for the Care and Use of Animals for Experimental Purposes in Australia. The adenosine A2A receptor knockout mice used in the present study were bred on a CD-1 background, originally obtained from C Ledent (IRIBHN, Belgium). Wild-type mice used in the study were obtained from litters generated by heterozygous breeders. Mice were backcrossed for eight generations and were genotyped by routine PCR (Snell et al, 2000). All experiments were performed with adult male mice housed at the Integrative Neuroscience Facility, Howard Florey Institute. Mice used for intravenous self-administration were singly housed in a 12 h reverse light-dark cycle (dark 0700–1900 hours). Nesting material was available. Mice used in conditioned place preference and locomotor sensitization experiments were group housed (typically four per cage) with nesting material available and free access to food (standard mouse chow) and water.
Morphine hydrochloride and cocaine hydrochloride were obtained from Glaxo Australia Pty Ltd (Boronia, Australia) and dissolved in sterile 0.9% saline. Ketamine was obtained from Parnell Laboratories (Alexandria, Australia) and midazolam from Roche Products (Dee Why, Australia), and both drugs were diluted with 0.9% saline. Neomycin sulfate was supplied by Delta Veterinary Laboratories (Hornsby, Australia) and was diluted in heparinized (10 U) 0.9% saline. Meloxicam was obtained from Boeringher Ingleheim (Inglehiem, Germany).
Operant self-administration of oral sucrose or intravenous morphine (0.1 mg/kg/infusion) was assessed using operant chambers (model ENV-307W, Med Associates, Vermont, USA) that were equipped with two levers, one paired with reward delivery (the active lever) and one which resulted in no outcome when pressed (the inactive lever). A stimulus light (conditioned stimulus, CS) was located above the active lever and flashed on for a period of 10 s when the active lever was pressed and drug/sucrose delivered. In addition to this visual cue, a tray was placed under the grid below the active lever with a piece of paper (1 × 1 cm) upon which two drops of vanilla essence was placed before each session. The vanilla-infused paper provided an olfactory cue (unconditioned stimulus, US) for the location of the active lever. The chambers were housed in sound attenuated boxes and ventilated with fans.
Self-Administration Protocol: Natural Reinforcement
Mice were engaged in an instrumental learning task for up to 8 days. The reward obtained was a delivery of sucrose to a liquid receptacle in the chamber (5 μl), and reward delivery was contingent upon an active lever press. A fixed ratio of 1 (FR1) active lever press per sucrose delivery was employed. All sessions were 2 h in length and held in the dark phase of the photoperiod at approximately the same time each day. Mice were assessed for self-administration of sucrose at concentrations of 2.5, 5, or 10%.
Mice were anaesthetized using isofluorane (1.5–1.8%). and then implanted with indwelling venous cannulae (modified from Griffin and Middaugh, 2003). The cannulae consisted of a 3.5 mm length silastic tubing (inner diameter 0.012 inches × outer diameter 0.025 inches, Dow Corning Corporation, Midland, MI, USA) attached to a 22-gauge needle which was bent into U shape, then bent again at right angles to the luer. The catheter was inserted 1 cm into the jugular vein and anchored with suture. The remaining tubing ran subcutaneously behind the ear to exit on top of the head. The catheter port was attached to the skull using Loctite 454 instant adhesive (Loctite Australia Pty Ltd, Caringbah, Australia) followed by dental cement (Vertex-Dental, Zeist, Netherlands). While still under anesthesia the catheter was flushed with heparinized antibiotic (0.03 ml neomycin sulfate 4 mg/ml in 10 U heparin) and meloxicam (0.1 ml of 5 mg/ml, i.p.) was administered for pain relief. After surgery mice were allowed to recover for 24 h before training began. The day after surgery, the catheters were flushed with heparinized antibiotic and subsequent to that, heparinized saline twice daily to maintain catheter patency (typically before and after self-administration session). The patency of the catheters was evaluated periodically using 0.02–0.03 ml of ketamine (15 mg/ml) and midazolam (0.75 mg/ml) solution. If prominent signs of hypnosis were not apparent within 3 s of infusion the mouse was removed from the experiment.
Self-Administration Protocol: Morphine Reinforcement
Mice were connected via the jugular catheter to an intravenous line (Tygon, inner diameter 0.02 inches, outer diameter 0.06 inches) connected to a 22-gauge swivel (Instech Solomon, Plymouth Meeting, PA, USA). The swivel was connected to a syringe held in the infusion pump (model PHM-100SVA; Med Associates) with Bcoex-T22 tubing (inner diameter 0.24 inches × outer diameter 0.64 inches; Instech Soloman). As with responding for the natural reinforcer, CS and US were present and an FR1 schedule was employed. The injection volume was 19 μl and duration of injection was 2.3 s. A maximum of 50 drug infusions was set to prevent overdose, as well as a 10 s time-out period after each drug infusion. During the time-out period active lever presses were recorded but no drug infusion occurred. All sessions were 2 h in length unless 50 infusions were obtained (at which point the session was terminated) and held in the dark phase of the photoperiod, at approximately the same time each day. Initially mice were trained on cocaine (1 mg/kg per infusion, 1 day) before being moved onto morphine (0.1 mg/kg per infusion). Criteria were set at >6 infusions per session, a lever discrimination of at least 65% and less than 20% variation between infusions over 3 days. Mice who failed to meet criteria were excluded from the study. Subsequently, an additional cohort of mice (n=8–14) were cannulated and their responding for morphine at a higher dose (0.2 mg/kg per infusion) was assessed.
‘Breakpoint’ was assessed using a PR schedule. Breakpoint represents the point at which an animal ceases to press the active lever for a drug infusion when the instrumental requirement is progressively increased. This reflects the motivation of an animal to self-administer a given drug and may therefore provide more accurate data pertaining to the reinforcing efficacy of that drug (Arnold and Roberts, 1997). The PR protocol utilized was modified from Thomsen et al, 2005, with 0.1 mg/kg morphine delivered per infusion. The breakpoint was defined as the last completed ratio, after which a period of 60 min ensued where no reinforcer was earned. If this did not occur, the session was terminated after 2 h and the breakpoint was defined as the final ratio completed within the 2 h session. Although a ‘true breakpoint’ as defined by Arnold and Roberts (1997) may not be reached in a 2 h session, the data yielded still provide useful information regarding the motivation to obtain a drug reward. In addition, this session length has been reliably used previously, both in rats (Cornish et al, 2008; Clemens et al, 2006) and mice (Soria et al, 2006; Trigo et al, 2006). After 3 weeks abstinence in the home cage, drug-seeking was precipitated by placing mice into the operant chambers with the US present. Drug-seeking was assessed under extinction conditions (FR1 response resulted in CS but no infusion of morphine) for 1 h. There was no maximum set as there was no risk of overdose.
Morphine-Induced Conditioned Place Preference
The conditioned place preference apparatus (Lafayette Instruments, IN, USA) consisted of two main compartments with differences in visual (wall patterns) and tactile (floor texture) cues, separated by a neutral compartment. The light intensity settings were set at 30 (80 lux) within the conditioning compartments and 90 (380 lux) in the central compartment, with these values referring to the settings on the equipment provided. Before each session mice were habituated to the experimental room for at least 30 min. On day 1 (habituation), mice were placed in the central compartment and allowed free access to all three compartments for 15 min. The time spent in each compartment, as well as general locomotor activity, was recorded via horizontal optic sensor beams and specific software for the apparatus (Motor Monitor; Kinder Scientific, CA, USA). Locomotor activity was measured as the number of beam breaks, referred to as ‘activity counts’. On days 2–9 (the conditioning phase) mice received alternating injections of morphine (10 mg/kg, i.p.) or vehicle and were immediately confined into one of the two conditioning compartments for 40 min (randomly allocated). On day 10 (test day), mice were once again allowed free access to all three compartments for 15 min. Place preference was determined as a positive difference between time spent in the drug-paired compartment on test day compared to the saline-paired compartment.
Sensitization to the locomotor responses induced by chronic morphine treatment was performed as previously described (McPherson and Lawrence, 2006). Briefly, locomotor activity responses induced by morphine (10 mg/kg, i.p.) or vehicle were evaluated using photo-optic locomotor cells (Truscan Photobeam; Coulbourn Instruments, Allentown, PA, USA) in a low luminosity (20 lux), controlled environment. Movement was measured over x and y axes by optic sensor beams. Before each session, mice were habituated to the experimental room for at least 30 min. Mice were habituated to the locomotor cells for 40 min per day over 3 consecutive days. On days 4–8, mice were placed in the locomotor cells immediately after morphine (10 mg/kg, i.p.) or vehicle injection, and their locomotor activity recorded for 40 min. Data were retrieved using Truscan software.
After completing chronic morphine or vehicle administration (days 4–8) mice remained without treatment in their home cage for 7 days (days 9–15). On day 16, mice received a challenge dose of morphine (5 mg/kg, i.p.) or vehicle and their locomotor activity was immediately measured for 40 min.
For morphine self-administration (0.1 mg/kg per infusion) a one-way ANOVA was performed on the total lever presses across the genotypes (active and inactive levers), with Student—Newman–Keuls post hoc analyses where appropriate. For time course analyses (morphine and sucrose self-administration, PR cumulative responses), and analyses of the effect of genotype and dose on morphine administration a two-way ANOVA was performed, followed by either Student—Newman–Keuls or Holm–Sikak post hoc tests where appropriate. The data for lever discrimination were not normally distributed, and therefore a Mann–Whitney rank sum test was employed to compare between the genotypes. Comparisons of the PR data between the genotypes and the latency to reach sucrose criteria were analyzed using an unpaired t-test. Drug-seeking data and conditioned place preference data were analyzed by one-way ANOVA, with Student—Newman–Keuls post-tests to compare the different treatment groups and genotypes. Time course locomotor data were analyzed by three-way ANOVA with time, treatment, and genotype as factors, followed by Student—Newman–Keuls post hoc analyses where appropriate. Differences were deemed statistically significant if p<0.05.
Self-Administration of Sucrose is Similar in A2A Knockout and Wild-Type Mice
As shown in Figures 1a, c, and e, no difference was observed between wild-type and A2A receptor knockout mice with respect to self-administration of sucrose, a natural reinforcer, over a range of concentrations. Two-way repeated-measures ANOVA revealed no effect of genotype (p>0.05). There was no difference between the genotypes (p>0.05) with respect to latency to criteria (defined as 70 sucrose rewards in a single 2 h session). Analysis of discrimination data by Mann–Whitney rank sum tests revealed no difference between genotypes at 2.5 and 10% (p>0.05) but a difference at 5% (t=947, p<0.01) with A2A receptor knockout mice displaying slightly worse discrimination for the active lever (83%) compared to wild type (94%) at this dose (data not shown).
Decreased Self-Administration of Morphine on FR1 and PR Schedules in A2A Knockout Mice Compared to Wild Type
Both wild-type and A2A receptor knockout mice reliably self-administered morphine at a dose of 0.1 mg/kg per infusion (Figure 2a). Analysis of aggregate data by two-way ANOVA revealed a main effect of lever identity (F(1,417)=160.937, p<0.001). Student—Newman–Keuls post hoc comparisons revealed a significant preference for the active lever over the inactive lever in both wild-type (q=18.199, p<0.001) and A2A knockout mice (q=7.2213, p<0.001), demonstrating that both genotypes exhibited significant discrimination in favor of the morphine-paired lever (see Figure 2a). Despite both genotypes displaying high discrimination for the morphine-paired lever, the level of discrimination was impaired in A2A knockout mice compared to wild type. Analysis of the lever discrimination data via a Mann–Whitney rank sum test revealed a significantly lower discrimination for the active lever in A2A knockout mice compared to wild type (t=134, p<0.05, data not shown).
As shown in Figures 2a and b, self-administration of morphine at the dose tested was significantly attenuated in A2A knockout mice compared to wild-type mice. Analysis by two-way ANOVA revealed a main effect of genotype (F(1,417)=10.175, p<0.01) and a significant interaction between lever (active vs inactive) and genotype (F(1,29.674), p<0.001; Figure 2a). Student—Newman–Keuls post hoc comparisons revealed significant differences between genotypes within active lever presses (q=8.648, p<0.001). Analysis of the number of morphine infusions over the 7-day period revealed a significant effect of genotype (two-way ANOVA; F(1,184)=28.948, p<0.001). Student—Newman–Keuls post hoc analysis revealed that the genotype difference in infusions received and therefore the amount of morphine self-administered was evident on every day of self-administration (p<0.05).
Analysis of an additional cohort of mice at a higher dose of morphine (0.2 mg/kg per infusion) revealed similar results. As can be seen in Figure 2c, A2A knockout mice also self-administered less morphine at this higher dose. Analysis by two-way ANOVA revealed a significant effect of genotype (F(1,270)=20.728, p<0.001) and dose (F(1,270)=55.547, p<0.001) but no interaction between these (p>0.05). Figure 2d displays representative event records for each genotype from an FR1 session (0.1 mg/kg per infusion), illustrating the pattern of drug self-administration within a session.
In addition to decreased baseline morphine self-administration, A2A receptor knockout mice displayed a lower breakpoint compared to wild type when assessed using a PR schedule. As shown in Figures 3a, b, and c, unpaired t-tests revealed a significant difference between genotypes with respect to the final ratio obtained (breakpoint) (t=4.263, p<0.001), as well as the total number of lever presses for the session (t=3.694, p<0.001) and the number of drug infusions obtained (t=3.967, p<0.001). When assessing the proportion of mice that reached a ‘true breakpoint’ (when no reinforcer is earned for a 60 min period) it was discovered that 9 out of 17 knockout mice (53%) did indeed reach a ‘true breakpoint’ in the 2 h session, whereas only 2 from 16 wild-type mice (12.5%) did. This is apparent when examining the cumulative response record (Figure 3d) as one can observe a clear plateau in the responding of A2A knockout mouse but not for the wild-type mice. Analysis of cumulative response record data (Figure 3d) by two-way ANOVA revealed a significant effect of genotype (F(1,341)=10.980, p<0.01) and time (F(11,341)=38.698, p<0.001), and a significant interaction between the two factors (F(11,341)=7.872). Holm–Sidak post hoc comparisons revealed that there was no difference between wild-type and knockout mice in the first four time bins (p>0.05) but cumulative responses were significantly reduced in A2A knockout mice compared to wild type in every 10 min time bin from 50 to 120 min (t=2.438, 2.948, 3.197, 3.666, 3.883, 4.017, 4.649 and 4.991, respectively, p<0.05). A plateau in responding was evident from 80 min onward for knockout mice. The cumulative levels of lever pressing at the 80 min time point were significantly higher than the 10 min time point for both A2A knockout (t=3.954, p<0.001) and wild-type mice (t=9.904, p<0.001). When comparing the cumulative levels of responding between the last time bin (110–120 min) and the 80 min time point, a similarly significant increase was found in wild-type mice (t=3.376, p<0.01). This was not the case for A2A knockout mice; there was no significant difference between any time bin between 80 and 120 min (t=0.936, p>0.05), suggesting a plateau in active lever responding had occurred.
Both A2A Knockout and Wild-Type Mice Exhibit Robust Cue-Conditioned Morphine-Seeking Behavior after a Period of Withdrawal
Despite the significant differences in FR1 and PR sessions as described above, both genotypes exhibited robust cue-conditioned drug-seeking behavior after a period of 3 weeks abstinence (Figure 4). Lever presses on the active lever were significantly higher on test day (1 h session) compared to baseline responding (2 h session), despite the absence of drug infusions during the session. This significant cue-conditioned drug-seeking response for both genotypes was revealed by one-way ANOVA (F(3,59)=13.12), and Student—Newman–Keuls post hoc analyses for both wild-type (q=4.692, p<0.001) and A2A knockout mice (q=7.578, p<0.001), confirming enhanced responding on the active lever on test day compared to the FR1 schedule. There was, however, no difference between genotypes in active lever presses on the test day (q=0.9493, p>0.05).
Absence of Conditioned Place Preference to Morphine in A2A Knockout Mice
As Figure 5a demonstrates, a conditioned place preference to morphine (10 mg/kg, i.p.) was observed in wild-type mice but not in A2A knockout mice. One-way ANOVA revealed a significant effect of treatment (F(3,44)=4.131, p<0.01) and a post hoc Student—Newman–Keuls multiple comparison test revealed a significant difference between time spent in the morphine-paired compartment vs time spent in the saline-paired compartment on test day in wild-type mice (q=4.953, p<0.01), but not knockout mice (p>0.05).
A2A Knockout Mice Fail to Display Tolerance to the Locomotor-Activating Properties of Morphine
During the preconditioning session locomotor activity was not significantly different between the two genotypes (data not shown). Time course data over the 4 days of morphine conditioning were analyzed by a two-way ANOVA, followed by Student—Newman–Keuls post hoc analyses where appropriate. As can be seen in Figure 5b, an effect of genotype was determined (F(1,82)=21.54, p<0.001), and although there was no difference between genotypes on the first day of morphine treatment (q=0.572, p>0.05), the level of morphine-induced locomotor activity in wild-type mice was significantly less than that observed in A2A receptor knockout mice on days 2 (q=4.264, p<0.01), 3 (q=3.949, p<0.01), and 4 (q=5.011, p<0.001).
The locomotor response to morphine in wild-type mice actually decreased to a point where it was not significantly different from the locomotor response to saline. This was revealed by a two-way ANOVA within genotypes. In wild-type mice, the response to morphine was significantly higher than the response to saline on days 1–3 (q=6.060, 5.108, and 5.026, respectively, p<0.001) but not day 4 (q=0.997, p>0.05). In contrast, for A2A receptor knockout mice, the locomotor response to morphine was significantly higher than that to saline on days 2, 3, and 4 (q=3.549, 4.964, and 3.477 respectively, p<0.001). Furthermore, the sustained hyperactive response to morphine in A2A knockout mice during place conditioning was confirmed with the locomotor cell data obtained during the chronic treatment regime for the sensitization protocol (Figure 6a). Student—Newman–Keuls post hoc analysis following a two-way ANOVA revealed that the locomotor activity on the last day of morphine treatment was significantly decreased in wild-type mice compared to the first day (q=6.235, p<0.001). This was not the case for A2A receptor knockout mice (q=1.192, p>0.05).
A2A Receptor Deletion does not Alter the Expression of Behavioral Sensitization to Morphine
Behavioral sensitization to morphine was observed in both knockout and wild-type mice. As can be seen in Figure 6b, there was an increase in the locomotor response on challenge day in the mice pretreated with morphine compared to mice pretreated with saline. Three-way ANOVA revealed a significant effect of treatment (F(1,288)=43.918, p<0.001) and time bin (F(7,288)=9.430, p<0.001), but not genotype (F(1,288)=0.556, p=0.457).
The current study demonstrates a key role for the adenosine A2A receptor in the centrally mediated effects of morphine. We have shown that deletion of the adenosine A2A receptor results in decreased self-administration of morphine as well as a decreased breakpoint on a PR schedule. In addition, at the dose and conditions tested, A2A knockout mice did not acquire a conditioned place preference to morphine, nor develop tolerance to the locomotor-activating properties of morphine. Despite this pronounced reward-related phenotype in mice devoid of the A2A receptor, this receptor is not necessary for the expression of behavioral sensitization to morphine or cue-conditioned initial drug-seeking after a period of withdrawal, as both of these behaviors were intact in A2A knockout mice.
Potential differences in the ‘hedonic’ value of morphine were evaluated using conditioned place preference. Rewarding effects of morphine were revealed in wild-type mice, as previously reported (Pchelintsev et al, 1991), but these effects were absent in mice lacking the A2A receptor, under the current experimental paradigm. The possibility of a learning impairment is unlikely, as both A2A knockout and wild-type mice readily acquired the instrumental learning task for sucrose self-administration. In addition, it has been reported that mice lacking the A2A receptor actually display enhanced spatial recognition memory (Wang et al, 2003), and should presumably have no learning impairment in a conditioned place preference paradigm on this basis. Hence, these results concur with a decreased reward value of morphine in A2A knockout mice. The possibility that the dose–response curve to morphine has shifted in the opposite direction in A2A knockout mice cannot be completely ruled out however. A decreased place preference in A2A receptor knockout mice has also been observed for THC (Soria et al, 2004) and nicotine (Castane et al, 2006), but not for cocaine (Soria et al, 2006), indicating a differential role for the A2A receptor with regard to different drugs of abuse.
A2A knockout mice reliably maintained self-administration of morphine, though the level of self-administration was markedly reduced when compared to wild-type mice. This decrease in morphine self-administration was observed for both doses tested. The effect of genotype appears to be specific to drug reinforcers, as no genotype difference in sucrose self-administration was observed over a range of concentrations. Decreased self-administration of morphine following A2A receptor deletion is in agreement with previous pharmacological studies. The adenosine A2 receptor antagonist DMPX reduces morphine self-administration in rats whereas CGS21680, a selective adenosine A2 receptor agonist, increases morphine self-administration (Sahraei et al, 1999). Our data suggest a possible decreased ‘reward value’ of morphine in A2A knockout mice and implicate the A2A receptor in the reinforcing properties of morphine. An inability for A2A receptor knockout mice to develop a conditioned place preference for the morphine-paired chamber is consistent with this finding, as is the reduced breakpoint on the PR schedule observed in the operant responding paradigm. Over half of the A2A knockout mice assessed reached a true breakpoint during the 2 h session. This figure was only 12.5% for wild-type mice which suggests that the true breakpoint for wild-type mice may be even higher than that reported here. A lower breakpoint in A2A knockout mice implies decreased motivation to obtain a reward and therefore further implicates the A2A receptor in the incentive/motivational properties of morphine. Inherent issues exist in the interpretation of FR1 data with respect to ‘reinforcing efficacy’ of drugs (Arnold and Roberts, 1997). In contrast, PR schedule data in the form of breakpoint, response records, and the number of infusions administered during a session provide invaluable information regarding the motivational drive to obtain a drug reward. The fact that A2A knockout mice displayed a reduction in all of these parameters certainly supports the hypothesis of impaired morphine reward as a result of A2A receptor deletion. The possibility of the inverse occurring—that the reward value of morphine is increased in A2A knockout mice, hence causing a reduction in morphine self-administration due to an increased sensitivity—cannot be ruled out, but is unlikely, as one would not expect in this scenario to observe such a poor performance by the knockout mice on a PR schedule compared to wild type. In addition, a place preference to morphine was absent in A2A knockout mice, and FR1 event records for self-administration showed similar bunching of infusions between genotypes.
A decrease in the reward value of morphine as a result of A2A receptor deletion is consistent with findings with other drugs of abuse. Soria et al (2006) observed decreased self-administration of cocaine and a reduced breakpoint on a PR in the same line of A2A knockout mice. Our findings support the hypothesis proposed by these authors, that A2A knockout mice represent a phenotype of low vulnerability to drug addiction and that absence of the A2A receptor could provide resistance against the addictive properties of drugs of abuse such as cocaine, and now opiates.
The rewarding effects of morphine are primarily due to actions on μ-opioid receptors (Contet et al, 2004), in part by an increase in firing rate of midbrain dopaminergic neurons, mediated by inhibition of GABAergic interneurons within the ventral tegmental area (VTA), enhancing release of dopamine in the NAc (Johnson and North, 1992). A functional hypodopaminergic state exists in A2A knockout mice (Dassesse et al, 2001) and two studies have demonstrated increased expression of D1 and D2 mRNA in the striatum of these mice (Dassesse et al, 2001; Short et al, 2006b), a finding consistent with models of decreased dopaminergic function (Fang et al, 1997; Smith et al, 1997). A decreased dopaminergic state would be in line with decreased reward in A2A receptor knockout mice. A2A receptors are colocalized with D2 receptors on striatopallidal neurons, can form heterodimers (Canals et al, 2003), and also interact in an antagonistic fashion. A direct effect in the form of removal of the A2A receptor-mediated antagonism of D2 receptor-mediated effects is unlikely to be the mechanism by which A2A receptor deletion modulates morphine reward. If this were the case one would expect an increased reward value of morphine in A2A knockout mice, and not the opposite, as we and other researchers have observed.
Interactions between A2A and D2 receptors may be more complex than as described above, though, as for example, a synergistic relationship between D2 and A2A receptors was observed in relation to protein kinase A signaling in ethanol consumption (Yao et al, 2002). In support of D2–A2A receptor synergy, with respect to opioids, Yao et al (2003) demonstrated that A2A receptor antagonists abolish synergistic actions between opioids and dopamine D2 receptors. Dopamine- and cyclic AMP (cAMP)-regulated phosphoprotein of 32 kDa (DARPP-32) is a downstream effector molecule of dopamine receptors and it has been shown that the A2A antagonist, SCH 58261, counteracts the increase in Thr34-DARPP-32 phosphorylation observed following treatment with selective D2 receptor antagonists (Svenningsson et al, 2000). This is particularly relevant in the context of morphine reward, as DARPP-32 phosphorylation at Thr34 is increased following morphine administration (Lindskog et al, 1999). In addition, despite segregation on a separate striatal output pathway, dopamine D1 receptors have also been shown to interact with A2A receptors at a ‘network level’, therefore influences of A2A receptors on morphine reward by interactions with D1 receptors cannot be dismissed (Short et al, 2006a).
Administration of moderate doses of morphine to rats produces a biphasic locomotor response, consisting of an initial reduction followed by an increase in locomotor activity (Babbini and Davis, 1972). A similar acute locomotor response to morphine was observed in both A2A knockout and wild-type mice, indicating the A2A receptor is not involved in mediating the acute psychomotor response to morphine. Activation of dopamine D1 receptors located on striatal medium spiny neurons is involved in the acute psychomotor effect of morphine. Thus, the increase in locomotion elicited by morphine can be prevented by systemic administration of SCH23390, a dopamine D1 receptor antagonist (Jeziorski and White, 1995; Serrano et al, 2002), and is absent in D1 receptor knockout mice (Becker et al, 2001). In contrast, the increase in motor activity produced by morphine in dopamine D2 receptor knockout mice does not differ from that observed in wild-type littermates (Maldonado et al, 1997). The D1 receptor-mediated effect is dependent on activation of the cAMP/PKA/DARPP-32 pathway (Borgkvist and Fisone, 2007). Despite the decrease in locomotor response elicited in DARPP-32 mutant mice following morphine administration, conditioned place preference and locomotor sensitization to morphine were observed. These data suggest that morphine reward and psychomotor stimulation are separate neuronal processes, the latter being dependent on activation of D1 receptors. Adenosine A2A receptors are not expressed on striatonigral neurons with D1 receptors (Rosin et al, 2003). This may explain the absence of A2A receptor involvement in the mediation of the acute locomotor-activating properties of morphine.
Tolerance to the locomotor-activating properties of morphine was observed in wild-type but not A2A knockout mice, suggesting a perturbation of the cellular and molecular processes underlying tolerance as a result of A2A receptor deletion. Tolerance to opiates is proposed to be due to upregulation of the adenylate cyclase/cAMP/PKA pathway (Nestler, 1996). Adenosine is formed from cAMP both inside and outside the cell (Hack and Christie, 2003). Morphine dose dependently increases adenosine release (Sandner-Kiesling et al, 2001), perhaps by inhibition of adenosine uptake (Halimi et al, 2000). Sensitivity to exogenous adenosine is increased at excitatory synapses in the NAc following chronic morphine treatment (Brundege and Williams, 2002), and chronic morphine treatment results in an upregulation of adenosine transporters in the striatum (Kaplan and Leite-Morris, 1997). Furthermore, an increased severity in some withdrawal symptoms has been observed in A2A knockout mice (Bailey et al, 2004), and this is confined to withdrawal symptoms that are locomotor in nature (paw shakes and withdrawal jumping).
Repeated exposure to morphine causes an increase in motor stimulation induced by a subsequent morphine challenge, an effect known as sensitization (Babbini and Davis, 1972; Lett, 1989). This behavioral (and presumably incentive) sensitization is believed to reflect some of the motivational aspects of drug addiction, such as craving and drug-seeking (Robinson and Berridge, 1993). Previous work has suggested a role for adenosine in morphine sensitization (Weisberg and Kaplan, 1999). Adenosine A2A knockout mice sensitized to morphine in the current study indicating that the A2A receptor is not necessary for the development or expression of sensitization to morphine. This is consistent with the finding that selective A1 receptor antagonists inhibit the development of morphine sensitization in mice (Weisberg and Kaplan, 1999), suggesting that any role that adenosine may play in morphine sensitization is likely mediated by the A1 receptor.
Previous work has demonstrated a definitive role for glutamate, but not necessarily dopamine, in behavioral sensitization to morphine (Vanderschuren and Kalivas, 2000). In addition, the VTA appears to be the site important for the development of sensitization to opiate agonists (Vanderschuren and Kalivas, 2000). Thus, opioid receptor antagonist administration to the VTA, but not the NAc, blocks the development of sensitization (Kalivas and Duffy, 1987), and morphine administration to the VTA, but not the NAc, causes sensitization (Vezina et al, 1987). Involvement of the VTA as opposed to the NAc supports the lack of involvement of the A2A receptor in induction of morphine sensitization as the A2A receptor is not localized within the VTA (Rosin et al., 1998). Thus, it is afferents projecting to the VTA (such as corticotegmental inputs) that would be presumably the anatomical substrates for this process, as opposed to the medium spiny neurons of the striatopallidal neurons where A2A receptors are predominantly located.
In contrast, the expression of behavioral sensitization to morphine does appear to involve the NAc (Vanderschuren and Kalivas, 2000). There are presynaptic A2A receptors located on cortical glutamatergic afferents to the NAc and these have been shown to form heterodimers with A1 receptors able to regulate glutamate release (Ciruela et al, 2006). Despite a role for the A2A receptor in presynaptic regulation of glutamatergic input to the NAc, deletion of the A2A receptor does not prevent the expression of behavioral sensitization to morphine. This suggests the drug-induced plasticity resulting from repeated morphine administration can occur in the absence of the A2A receptor, though adaptive compensation in A2A knockout mice cannot be ruled out.
In humans, drug-associated stimuli is important in drug relapse after prolonged abstinence (Kalivas and Volkow, 2005). In animals, cue-conditioned drug-seeking is said to model the formation of contextual/cued associations with drugs of abuse in humans (Shaham et al, 2003). Significant studies have shown that cue-induced drug-seeking increases over time during abstinence, leading to the concept of ‘incubation of craving’ (Grimm et al, 2001). This is a robust phenomenon that has been observed across a number of different drug classes in rats (Di Ciano and Everitt, 2004; Grimm et al, 2002; Shalev et al, 2001; Lu et al, 2007). Moreover, this type of delayed onset craving can be present in human cocaine users (Kosten et al, 2005). Both wild-type and A2A knockout mice exhibited robust cue-induced drug-seeking behavior, under extinction conditions (no drug delivery) following a 3-week withdrawal period. These data are consistent with the hypothesis that incubation of craving for an opiate occurs in mice. Increased drug-seeking behavior is most likely a result of neuroadaptations that occur over time with repeated drug administration. Absence of the A2A receptor does not affect cue-induced drug-seeking behavior following a period of withdrawal. This suggests that the lack of A2A receptors does not prevent the pathophysiological changes that contribute to compulsive drug-seeking behavior, despite mutant mice showing a reduced level of morphine self-administration. Importantly, although a number of brain nuclei have been implicated in cue-induced drug-seeking following extinction, there appears to be a critical role for the basolateral amygdala in this process (Fuchs and See, 2002), an area essentially devoid of A2A receptors (Rosin et al, 1998). A recent study (Yao et al, 2006) found that intra-accumbal administration of the A2A receptor antagonist DMPX reduced heroin-primed reinstatement of heroin-seeking in rats, confirming the involvement of multiple brain nuclei in reinstatement of drug-seeking. Importantly, there are network differences between drug-primed drug-seeking and cue-induced drug-seeking that could contribute to these apparently opposing results (Shaham et al, 2003). Clearly, further studies are warranted to explore in detail the role of the adenosine A2A receptor in the process of extinction and subsequent reinstatement. Moreover, our data suggest that mice are a suitable species to probe the genetics and mechanism(s) behind incubation of craving.
In conclusion, under the conditions of our experiments, our data are consistent with a putative dislocation in the role of the A2A receptor in the acute rewarding effects of morphine and the drug-induced plasticity occurring as a result of repeated morphine administration. This is demonstrated by decreased morphine reward in A2A knockout mice, but intact psychomotor sensitization and cue-conditioned initial drug-seeking following a period of withdrawal.
Arnold JM, Roberts DC (1997). A critique of fixed and progressive ratio schedules used to examine the neural substrates of drug reinforcement. Pharmacol Biochem Behav 57: 441–447.
Arolfo MP, Yao L, Gordon AS, Diamond I, Janak PH (2004). Ethanol operant self-administration in rats is regulated by adenosine A2 receptors. Alcohol Clin Exp Res 28: 1308–1316.
Babbini M, Davis WM (1972). Time–dose relationships for locomotor activity effects of morphine after acute or repeated treatment. Br J Pharmacol 46: 213–224.
Bailey A, Davis L, Lesscher HM, Kelly MD, Ledent C, Hourani SM et al (2004). Enhanced morphine withdrawal and mu-opioid receptor G-protein coupling in A2a adenosine receptor knockout mice. J Neurochem 88: 827–834.
Becker A, Grecksch G, Kraus J, Peters B, Schroeder H, Schulz S et al (2001). Loss of locomotor sensitisation in response to morphine in D1 receptor deficient mice. Naunyn Schmiedebergs Arch Pharmacol 363: 562–568.
Berrendero F, Castane A, Ledent C, Parmentier M, Maldonado R, Valverde O (2003). Increase of morphine withdrawal in mice lacking A2a receptors and no changes in CB1/A2a double knockout mice. Eur J Neurosci 17: 315–324.
Borgkvist A, Fisone G (2007). Psychoactive drugs and regulation of the camp/pka/darpp-32 cascade in striatal medium spiny neurons. Neurosci Biobehav Rev 31: 79–88.
Brundege JM, Dunwiddie TV (1997). Role of adenosine as a modulator of synaptic activity in the central nervous system. Adv Pharmacol 39: 353–391.
Brundege JM, Williams JT (2002). Increase in adenosine sensitivity in the nucleus accumbens following chronic morphine treatment. J Neurophysiol 87: 1369–1375.
Canals M, Marcellino D, Fanelli F, Ciruela F, de Benedetti P, Goldberg SR et al (2003). Adenosine A2a-dopamine D2 receptor-receptor heteromerization: qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer. J Biol Chem 278: 46741–46749.
Castane A, Soria G, Ledent C, Maldonado R, Valverde O (2006). Attenuation of nicotine-induced rewarding effects in A2a knockout mice. Neuropharmacology 51: 631–640.
Chen JF, Beilstein M, Xu YH, Turner TJ, Moratalla R, Standaert DG et al (2000). Selective attenuation of psychostimulant-induced behavioral responses in mice lacking A2a adenosine receptors. Neuroscience 97: 195–204.
Ciruela F, Casado V, Rodrigues RJ, Lujan R, Burgueno J, Canals M et al (2006). Presynaptic control of striatal glutamatergic neurotransmission by adenosine A1-A2a receptor heteromers. J Neurosci 26: 2080–2087.
Clemens KJ, Cornish JL, Hunt GE, McGregor IS (2006). Intravenous methamphetamine self-administration in rats: effects of intravenous or intraperitoneal MDMA co-administration. Pharmacol Biochem Behav 85: 454–463.
Contet C, Kieffer BL, Befort K (2004). Mu opioid receptor: a gateway to drug addiction. Curr Opin Neurobiol 14: 370–378.
Cornish JL, Clemens KJ, Thompson MR, Callaghan PD, Dawson B, McGregor IS (2008). High ambient temperature increases intravenous methamphetamine self-administration on fixed and progressive ratio schedules in rats. J Psychopharmacol 22: 100–110.
Dassesse D, Massie A, Ferrari R, Ledent C, Parmentier M, Arckens L et al (2001). Functional striatal hypodopaminergic activity in mice lacking adenosine A2a receptors. J Neurochem 78: 183–198.
Di Chiara G, Imperato A (1988). Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci USA 85: 5274–5278.
Di Ciano P, Everitt BJ (2004). Conditioned reinforcing properties of stimuli paired with self-administered cocaine, heroin or sucrose: implications for the persistence of addictive behaviour. Neuropharmacology 47 (Suppl 1): 202–213.
Dunwiddie TV (1985). The physiological role of adenosine in the central nervous system. Int Rev Neurobiol 27: 63–139.
Fang Y, Janowsky A, Ronnekleiv OK (1997). Cocaine exposure in fetal rhesus monkey: consequences for dopamine D1- and D2-like receptor binding densities. Brain Res Dev Brain Res 104: 163–174.
Ferre S, Fredholm BB, Morelli M, Popoli P, Fuxe K (1997). Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia. Trends Neurosci 20: 482–487.
Ferre S, Herrera-Marschitz M, Grabowska-Anden M, Casas M, Ungerstedt U, Anden NE (1991a). Postsynaptic dopamine/adenosine interaction: II. Postsynaptic dopamine agonism and adenosine antagonism of methylxanthines in short-term reserpinized mice. Eur J Pharmacol 192: 31–37.
Ferre S, Rubio A, Fuxe K (1991b). Stimulation of adenosine A2 receptors induces catalepsy. Neurosci Lett 130: 162–164.
Ferre S, Snaprud P, Fuxe K (1993). Opposing actions of an adenosine a2 receptor agonist and a gtp analogue on the regulation of dopamine D2 receptors in rat neostriatal membranes. Eur J Pharmacol 244: 311–315.
Fink JS, Weaver DR, Rivkees SA, Peterfreund RA, Pollack AE, Adler EM et al (1992). Molecular cloning of the rat A2 adenosine receptor: selective co-expression with D2 dopamine receptors in rat striatum. Brain Res Mol Brain Res 14: 186–195.
Fredholm BB, Abbracchio MP, Burnstock G, Daly JW, Harden TK, Jacobson KA et al (1994). VI. Nomenclature and classification of purinoceptors. Pharmacol Rev 46: 143–156.
Fredholm BB, AP IJ, Jacobson KA, Klotz KN, Linden J (2001a). International union of pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 53: 527–552.
Fredholm BB, Irenius E, Kull B, Schulte G (2001b). Comparison of the potency of adenosine as an agonist at human adenosine receptors expressed in Chinese hamster ovary cells. Biochem Pharmacol 61: 443–448.
Fuchs RA, See RE (2002). Basolateral amygdala inactivation abolishes conditioned stimulus- and heroin-induced reinstatement of extinguished heroin-seeking behavior in rats. Psychopharmacology (Berl) 160: 425–433.
Griffin III WC, Middaugh LD (2003). Acquisition of lever pressing for cocaine in C57Bl/6J mice: effects of prior Pavlovian conditioning. Pharmacol Biochem Behav 76: 543–549.
Grimm JW, Hope BT, Wise RA, Shaham Y (2001). Neuroadaptation. Incubation of cocaine craving after withdrawal. Nature 412: 141–142.
Grimm JW, Shaham Y, Hope BT (2002). Effect of cocaine and sucrose withdrawal period on extinction behavior, cue-induced reinstatement, and protein levels of the dopamine transporter and tyrosine hydroxylase in limbic and cortical areas in rats. Behav Pharmacol 13: 379–388.
Hack SP, Christie MJ (2003). Adaptations in adenosine signaling in drug dependence: therapeutic implications. Crit Rev Neurobiol 15: 235–274.
Halimi G, Devaux C, Clot-Faybesse O, Sampol J, Legof L, Rochat H et al (2000). Modulation of adenosine concentration by opioid receptor agonists in rat striatum. Eur J Pharmacol 398: 217–224.
Hettinger BD, Lee A, Linden J, Rosin DL (2001). Ultrastructural localization of adenosine A2a receptors suggests multiple cellular sites for modulation of GABAergic neurons in rat striatum. J Comp Neurol 431: 331–346.
Jeziorski M, White FJ (1995). Dopamine receptor antagonists prevent expression, but not development, of morphine sensitization. Eur J Pharmacol 275: 235–244.
Johnson SW, North RA (1992). Opioids excite dopamine neurons by hyperpolarization of local interneurons. J Neurosci 12: 483–488.
Kalivas PW, Duffy P (1987). Sensitization to repeated morphine injection in the rat: possible involvement of A10 dopamine neurons. J Pharmacol Exp Ther 241: 204–212.
Kalivas PW, Volkow ND (2005). The neural basis of addiction: a pathology of motivation and choice. Am J Psychiatry 162: 1403–1413.
Kaplan GB, Coyle TS (1998). Adenosine kinase inhibitors attenuate opiate withdrawal via adenosine receptor activation. Eur J Pharmacol 362: 1–8.
Kaplan GB, Leite-Morris KA (1997). Up-regulation of adenosine transporter-binding sites in striatum and hypothalamus of opiate tolerant mice. Brain Res 763: 215–220.
Kaplan GB, Sears MT (1996). Adenosine receptor agonists attenuate and adenosine receptor antagonists exacerbate opiate withdrawal signs. Psychopharmacology (Berl) 123: 64–70.
Kosten T, Sofuoglu M, Poling J, Gonsai K, Oliveto A (2005). Desipramine treatment for cocaine dependence in buprenorphine- or methadone-treated patients: baseline urine results as predictor of response. Am J Addict 14: 8–17.
Ledent C, Vaugeois JM, Schiffmann SN, Pedrazzini T, El Yacoubi M, Vanderhaeghen JJ et al (1997). Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2a receptor. Nature 388: 674–678.
Lett BT (1989). Repeated exposures intensify rather than diminish the rewarding effects of amphetamine, morphine, and cocaine. Psychopharmacology (Berl) 98: 357–362.
Lindskog M, Svenningsson P, Fredholm B, Greengard P, Fisone G (1999). Mu- and delta-opioid receptor agonists inhibit DARPP-32 phosphorylation in distinct populations of striatal projection neurons. Eur J Neurosci 11: 2182–2186.
Lu L, Uejima JL, Gray SM, Bossert JM, Shaham Y (2007). Systemic and central amygdala injections of the mGlur(2/3) agonist LY379268 attenuate the expression of incubation of cocaine craving. Biol Psychiatry 61: 591–598.
Maldonado R, Saiardi A, Valverde O, Samad TA, Roques BP, Borrelli E (1997). Absence of opiate rewarding effects in mice lacking dopamine D2 receptors. Nature 388: 586–589.
McPherson CS, Lawrence AJ (2006). Exposure to amphetamine in rats during periadolescence establishes behavioural and extrastriatal neural sensitization in adulthood. Int J Neuropsychopharmacol 9: 377–392.
Nestler EJ (1996). Under siege: the brain on opiates. Neuron 16: 897–900.
Pchelintsev MV, Gorbacheva EN, Zvartau EE (1991). Simple methodology of assessment of analgesics' addictive potential in mice. Pharmacol Biochem Behav 39: 873–876.
Pinna A, di Chiara G, Wardas J, Morelli M (1996). Blockade of A2a adenosine receptors positively modulates turning behaviour and c-fos expression induced by D1 agonists in dopamine-denervated rats. Eur J Neurosci 8: 1176–1181.
Pollack AE, Fink JS (1996). Synergistic interaction between an adenosine antagonist and a D1 dopamine agonist on rotational behavior and striatal c-fos induction in 6-hydroxydopamine-lesioned rats. Brain Res 743: 124–130.
Robinson TE, Berridge KC (1993). The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res Brain Res Rev 18: 247–291.
Rosin DL, Hettinger BD, Lee A, Linden J (2003). Anatomy of adenosine A2a receptors in brain: morphological substrates for integration of striatal function. Neurology 61: S12–S18.
Rosin DL, Robeva A, Woodard RL, Guyenet PG, Linden J (1998). Immunohistochemical localization of adenosine A2a receptors in the rat central nervous system. J Comp Neurol 401: 163–186.
Sahraei H, Motamedi F, Khoshbaten A, Zarrindast MR (1999). Adenosine A2 receptors inhibit morphine self-administration in rats. Eur J Pharmacol 383: 107–113.
Salem A, Hope W (1997). Effect of adenosine receptor agonists and antagonists on the expression of opiate withdrawal in rats. Pharmacol Biochem Behav 57: 671–679.
Sandner-Kiesling A, Li X, Eisenach JC (2001). Morphine-induced spinal release of adenosine is reduced in neuropathic rats. Anesthesiology 95: 1455–1459.
Schiffmann SN, Libert F, Vassart G, Vanderhaeghen JJ (1991). Distribution of adenosine A2 receptor mRNA in the human brain. Neurosci Lett 130: 177–181.
Serrano A, Aguilar MA, Manzanedo C, Rodriguez-Arias M, Minarro J (2002). Effects of DA D1 and D2 antagonists on the sensitisation to the motor effects of morphine in mice. Prog Neuropsychopharmacol Biol Psychiatry 26: 1263–1271.
Shaham Y, Shalev U, Lu L, De Wit H, Stewart J (2003). The reinstatement model of drug relapse: history, methodology and major findings. Psychopharmacology (Berl) 168: 3–20.
Shalev U, Morales M, Hope B, Yap J, Shaham Y (2001). Time-dependent changes in extinction behavior and stress-induced reinstatement of drug seeking following withdrawal from heroin in rats. Psychopharmacology (Berl) 156: 98–107.
Short JL, Drago J, Lawrence AJ (2006a). Comparison of ethanol preference and neurochemical measures of mesolimbic dopamine and adenosine systems across different strains of mice. Alcohol Clin Exp Res 30: 606–620.
Short JL, Ledent C, Drago J, Lawrence AJ (2006b). Receptor crosstalk: characterization of mice deficient in dopamine D1 and adenosine A2a receptors. Neuropsychopharmacology 31: 525–534.
Smith TS, Trimmer PA, Khan SM, Tinklepaugh DL, Bennett Jr JP (1997). Mitochondrial toxins in models of neurodegenerative diseases. II: elevated zif268 transcription and independent temporal regulation of striatal D1 and D2 receptor mRNAs and D1 and D2 receptor-binding sites in C57Bl/6 mice during MPTP treatment. Brain Res 765: 189–197.
Snell BJ, Short JL, Drago J, Ledent C, Lawrence AJ (2000). Characterisation of central adenosine A1 receptors and adenosine transporters in mice lacking the adenosine A2a receptor. Brain Res 877: 160–169.
Snyder SH (1985). Adenosine as a neuromodulator. Annu Rev Neurosci 8: 103–124.
Soria G, Castane A, Berrendero F, Ledent C, Parmentier M, Maldonado R et al (2004). Adenosine A2a receptors are involved in physical dependence and place conditioning induced by THC. Eur J Neurosci 20: 2203–2213.
Soria G, Castane A, Ledent C, Parmentier M, Maldonado R, Valverde O (2006). The lack of A2a adenosine receptors diminishes the reinforcing efficacy of cocaine. Neuropsychopharmacology 31: 978–987.
Svenningsson P, Le Moine C, Kull B, Sunahara R, Bloch B, Fredholm BB (1997). Cellular expression of adenosine A2a receptor messenger RNA in the rat central nervous system with special reference to dopamine innervated areas. Neuroscience 80: 1171–1185.
Svenningsson P, Lindskog M, Ledent C, Parmentier M, Greengard P, Fredholm BB et al (2000). Regulation of the phosphorylation of the dopamine- and cAMP-regulated phosphoprotein of 32 kDa in vivo by dopamine D1, dopamine D2, and adenosine A2a receptors. Proc Natl Acad Sci USA 97: 1856–1860.
Svenningsson P, Lindskog M, Rognoni F, Fredholm BB, Greengard P, Fisone G (1998). Activation of adenosine A2a and dopamine D1 receptors stimulates cyclic AMP-dependent phosphorylation of DARPP-32 in distinct populations of striatal projection neurons. Neuroscience 84: 223–228.
Thomsen M, Woldbye DP, Wortwein G, Fink-Jensen A, Wess J, Caine SB (2005). Reduced cocaine self-administration in muscarinic M5 acetylcholine receptor-deficient mice. J Neurosci 25: 8141–8149.
Trigo JM, Panayi F, Soria G, Maldonado R, Robledo P (2006). A reliable model of intravenous MDMA self-administration in naive mice. Psychopharmacology (Berl) 184: 212–220.
Vanderschuren LJ, Kalivas PW (2000). Alterations in dopaminergic and glutamatergic transmission in the induction and expression of behavioral sensitization: A critical review of preclinical studies. Psychopharmacology (Berl) 151: 99–120.
Vezina P, Kalivas PW, Stewart J (1987). Sensitization occurs to the locomotor effects of morphine and the specific mu opioid receptor agonist, DAGO, administered repeatedly to the ventral tegmental area but not to the nucleus accumbens. Brain Res 417: 51–58.
Wang JH, Short J, Ledent C, Lawrence AJ, van den Buuse M (2003). Reduced startle habituation and prepulse inhibition in mice lacking the adenosine A2a receptor. Behav Brain Res 143: 201–207.
Weisberg SP, Kaplan GB (1999). Adenosine receptor antagonists inhibit the development of morphine sensitization in the C57Bl/6 mouse. Neurosci Lett 264: 89–92.
Yang M, Soohoo D, Soelaiman S, Kalla R, Zablocki J, Chu N et al (2007). Characterization of the potency, selectivity, and pharmacokinetic profile for six adenosine A2a receptor antagonists. Naunyn Schmiedebergs Arch Pharmacol 375: 133–144.
Yao L, Arolfo MP, Dohrman DP, Jiang Z, Fan P, Fuchs S et al (2002). βγ dimers mediate synergy of dopamine D2 and adenosine A2 receptor-stimulated PKA signaling and regulate ethanol consumption. Cell 109: 733–743.
Yao L, Fan P, Jiang Z, Mailliard WS, Gordon AS, Diamond I (2003). Addicting drugs utilize a synergistic molecular mechanism in common requiring adenosine and Gi- βγ dimers. Proc Natl Acad Sci USA 100: 14379–14384.
Yao L, McFarland K, Fan P, Jiang Z, Ueda T, Diamond I (2006). Adenosine A2a blockade prevents synergy between mu-opiate and cannabinoid CB1 receptors and eliminates heroin-seeking behavior in addicted rats. Proc Natl Acad Sci USA 103: 7877–7882.
This work was supported by a program grant (236805) from the National Health and Medical Research Council of Australia of which AJL is a senior research fellow. An equipment grant from ANZ Trustees (William Buckland Foundation) contributed toward the purchase of mouse operant chambers.
Disclosure/Conflict of Interest
About this article
Cite this article
Brown, R., Short, J., Cowen, M. et al. A Differential Role for the Adenosine A2A Receptor in Opiate Reinforcement vs Opiate-Seeking Behavior. Neuropsychopharmacol 34, 844–856 (2009). https://doi.org/10.1038/npp.2008.72
- adenosine A2A receptor
- knockout mice
- intravenous self-administration
This article is cited by
The Adenosine A2A Receptor Activation in Nucleus Accumbens Suppress Cue-Induced Reinstatement of Propofol Self-administration in Rats
Neurochemical Research (2021)
Effects of the adenosinergic system on the expression and acquisition of sensitization to conditioned place preference in morphine-conditioned rats
Naunyn-Schmiedeberg's Archives of Pharmacology (2016)
Netrin-1 receptor-deficient mice show age-specific impairment in drug-induced locomotor hyperactivity but still self-administer methamphetamine
Effects of A2A adenosine receptor blockade or stimulation on alcohol intake in alcohol-preferring rats
CREB1 and CREB-binding protein in striatal medium spiny neurons regulate behavioural responses to psychostimulants